YouTube Facebook LinkedIn Google+ Twitter Xingrss  

Phase II Flub for Peregrine



September 24, 2012 | A week after releasing favorable Phase II results for the novel vascular-targeting immunotherapy for non-small cell lung cancer, bavituximab, study sponsor Peregrine Pharmaceuticals has announced "major discrepancies" in the trial. Peregrine blames the research oversight team in charge of the trial (they were blinded), but the announcement still resulted in plummeting Peregrine stock. Cancer Grace
Click here to log in.

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1


For reprints and/or copyright permission, please contact  Terry Manning, 781.972.1349 , tmanning@healthtech.com.